晚期前列腺癌的表观遗传调控与谱系可塑性
本文综述晚期前列腺癌中表观遗传调控与谱系可塑性的作用。抗雄激素治疗后可发展为去势抵抗性前列腺癌(CRPC)或神经内分泌前列腺癌(NEPC),DNA甲基化、染色质完整性与转录调控可及性在前列腺癌发生进展中仍起关键作用。理解表观遗传改变如何调控进展及与遗传调节因子的交互驱动NEPC,可能有助于更好的风险分层和更有效治疗方案。
要点
- 抗雄激素治疗后患者易发展为CRPC或NEPC。
- DNA甲基化、染色质完整性与转录可及性在前列腺癌进展中起关键作用。
- 表观遗传与遗传调节因子交互驱动NEPC,或助力风险分层与治疗优化。
核心结论
- 表观遗传改变调控前列腺癌进展,并与遗传调节因子交互驱动NEPC,可能帮助风险分层和更有效治疗。
研究设计与样本
- 综述类文章,汇总临床前研究与临床试验中CRPC或NEPC发展相关的遗传信号通路及表观遗传证据。
主要发现
- 接受抗雄激素治疗的患者更易发展为CRPC或NEPC。
- DNA甲基化、染色质完整性和转录调控可及性在前列腺癌发生和进展中仍起关键作用。
临床怎么用
- 深入理解表观遗传改变调控前列腺癌进展及与遗传调节因子交互驱动NEPC,可能帮助开发更好的风险分层和更有效治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer is the most common cancer and second leading cause of cancer-related death in American men. Antiandrogen therapies are part of the standard of therapeutic regimen for advanced or metastatic prostate cancers; however, patients who receive these treatments are more likely to develop castration-resistant prostate cancer (CRPC) or neuroendocrine prostate cancer (NEPC). In the development of CRPC or NEPC, numerous genetic signaling pathways have been under preclinical investigations and in clinical trials. Accumulated evidence shows that DNA methylation, chromatin integrity, and accessibility for transcriptional regulation still play key roles in prostate cancer initiation and progression. Better understanding of how epigenetic change regulates the progression of prostate cancer and the interaction between epigenetic and genetic modulators driving NEPC may help develop a better risk stratification and more effective treatment regimens for prostate cancer patients.
引用
- Ge R, Wang Z, Montironi R, et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol. 2020. PMID: 32139297. doi:10.1016/j.annonc.2020.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。